World Nephrology Congress

Paris, France   June 20-22, 2018

Program Schedule

Wednesday, June 20 , 10:00-10:35

Meetings International - Nephrology Meeting 2018 Conference Keynote Speaker Ghodrat A.Siami photo

Keynote Forum

Ghodrat A.Siami

Vanderbilt School of Medicine, USA

Title

Progress on 100 years of blood purification

Biography

Ghodrat A Siami is a professor of Medicine and Nephrology at Vanderbilt School of Medicine. He was promoted to Professor Emeritus in 2011, received 50 years Service Award from AMA, and published more than 100 Abstracts, original papers, editorials and book chapters. He was President of International Society for Apheresis and Vice President of Word Apheresis Association. He is on Editorial board of several journals and Reviewer for FDA. He is now a Emeritus member of ASN, ISN, and Emeritus Board member of ISFA. He was invited by NIH to teach Nephrology at Tehran School of Medicine and is Invited Speaker in more than 100 Congress all around the world. He Chaired Celebration of 100 years plasmapheresis Congress in Saint Petersburg Russia. 

Abstract

First plasma separation was done by Abel in 1913 USA. Rosenberg and Yurevitch performed the first plasmapheresis in 1913 in St. Petersburg, Russia. The 100 years anniversary was celebrated in April 2013 in St. Petersburg Russia. I was the Congress Chair Person. Phlebotomy was first used in 1520 and we still use it to treat
familial hyperchromatosis. Blood letting was the ancient way to treat patients. Leeches were also used to remove blood. Transfusion from animal to human was performed in 17 century. Moravits transfused RBC from one dog to another in 1906. The first transfusion was performed in Cleveland, Ohio in 1906. Haas performed dialysis in a dog in 1914 and in human in 1924. Cohn used blood component in WWII. Rotating Drum was used by Kolffin 1942. Nose used artificial liver in 1960. Malchesky did the first membrane, Thermofiltration, and Cryojel removal in the USA in 1978. Agishi, from Japan, performed double filtration in 1980. Siami  developed Cryo-filtration, and tandem with hemodialysis in USA. Eight types of LDL pheresis was developed. Today, we are able to do many advancedapheresis, Photo-pheresis Cryo-filtration, chemo and Immuno-adsorption. Today we have developed many advances in Blood Purification to treat many diseases, specially many different immunoadsorption columns for diseases specific to the patient. They all proven to be effective and safe.

Wednesday, June 20 , 10:35-11:10

Meetings International - Nephrology Meeting 2018 Conference Keynote Speaker R. Michael Culpepper photo

Keynote Forum

R. Michael Culpepper

University of South Alabama College of Medicine, USA

Title

Advances in management of autosomal dominant polycystic kidney disease (ADPKD)

Biography

Roy Michael Culpepper earned his MD from the University of Alabama in Birmingham (UAB) and completed post-doctoral training at Loma Linda University, California, and UAB, AL. He serves as Professor of Medicine and Nephrology at the University of South Alabama and has been Director of Nephrology and served on Board of Directors of the National Kidney Foundation and the regional dialysis Network 8.

Abstract

ADPKD accounts for 5-7% of patients requiring dialysis or kidney transplant worldwide. The natural course of the disease was first characterized in the 1950’s. The basis of the disorder is now known to involve 2 genes, PKD1 and PKD2 that account for about 85% and 15%, respectively, of disease in affected individuals. PKD1 mutations are associated with the more rapid decline in kidney function with an average age to reach end-stage disease of 50-55 year in males and slightly longer in females. Recent data demonstrate a clear relation between the rate of cyst growth, measured as total kidney volume (TKV), and the rate of decline in kidney function, measured as eGFE. Further research implicates AVP as a key factor in the stimulation of cyst growth and increase in TKV. A number of intracellular targets to slow cyst growth have been identified and clinical studies with long-acting somatostatin analogs and with the renal AVP V2 receptor antagonist tolvaptan have been completed. Two seminal studies with tolvaptan have shown sufficiently robust effects to slow increases in TKV and declines in GFR as to warrant approval for use in ADPKD patients for prolongation of kidney function. ERA-EDTA has devised a concise outline, based on TKV and patient characteristics, to guide clinicians in the choice of patients most likely to benefit from tolvaptan.

Wednesday, June 20 , 11:30-12:05

Meetings International - Nephrology Meeting 2018 Conference Keynote Speaker John D. Sullivan photo

Keynote Forum

John D. Sullivan

Boston University, USA

Title

The Impact of treatment modality on employment and the economic benefit above the cost of providing direct treatment

Biography

John D Sullivan is an expert in health care policy, finance, and asset valuation. Prior to joining Boston University, he worked for Fresenius Medical Care, completing the acquisitions of over one hundred health care companies with an estimated value of over $5 billion. In 2008, Sullivan co-founded Reliant Renal Care with private equity funding. He
has provided strategic guidance for many of the largest health care organizations in the United States. Sullivan presently teaches mergers and acquisitions, corporate finance, investments, and financial markets and institutions

Abstract

End Stage Renal Disease, or ESRD, impacts the lives directly of 660,000 for transplant, hemodialysis, and peritoneal dialysis patients. Much has been discussed and researched regarding to the type of treatment modalities via transplant, peritoneal dialysis, in-center hemo dialysis, and home hemodialysis and the ability to continue employment. Without including transplant, the treatment of ESRD on an on-going basis is quite expensive. Studies have shown that the cost of in-center hemodialysis is less expensive than both peritoneal dialysis (both CCPD and CCPD) and home hemodialysis due to the cost of supplies despite an advantage (or disadvantage depending on in center utilization). However, these studies have only concentrated on the cost and not the economic benefit in a quantitative nature. It is this study’s conclusion that home hemodialysis, despite its higher costs, as well as peritoneal dialysis, is the clear economic benefit to the United States health care system although may have the same economic drawbacks to peritoneal dialysis, but will certainly contribute above and beyond the simple cost analysis. This analysis also is correlation with studies that support these two modalities for treatment outcomes from a clinical perspective.

  • Workshop
    Location: Rome

Wednesday, June 20, 12:05-13:00

Meetings International - Nephrology Meeting 2018 Conference Session Speaker Simon Allen photo

Session Introduction

Simon Allen

Fine Treatment, UK

Title

Common non-infectious and non-malignant diseases of the urinary system and their therapeutic treatment with Dr Allen’s devices

Biography

Simon Allen obtained a PhD in Medicine in 1978, Dr Simon Allen specialised in internal medicine. For years, he worked at and subsequently headed a hospital’s cardio-vascular department, and treated patients with various internal diseases, including renal diseases. He authored many scientific articles on metabolic disorders, including obesity, arthritis, renal, cardio-vascular and gastroenterological diseases. He lectured doctors pursuing higher medical qualifications. He then devoted two decades to pioneering medical research into various chronic internal diseases. He established Fine Treatment in Oxford, UK, authored The Origin of Diseases Theory, invented and patented therapeutic Dr Allen’s Devices as effective tools of Thermobalancing therapy.

Abstract

10-year long empirical observations and 2 clinical trials have demonstrated high efficacy of therapeutic Dr Allen’s Devices in alleviation of symptoms and treatment of diseases of the renal/urinary system. Treatment progress with two innovative Dr Allen’s Devices, for kidney and prostate care, are assessed in this report. In most cases, chronic diseases of the renal system are not immediately life-threatening. Thus, the most optimal firstline treatment approach is therapeutic. It ensures no side effects for patients undergoing treatment. The renal system produces, stores and eliminates urine. The kidneys produce urine by filtering wastes and extra water from blood. Urine travels from the kidneys through two ureters and fills the bladder. When the bladder is full, a person urinates through the urethra to eliminate the waste. Health disorders may emerge in every part of this renal/urinary system. The most common kidney diseases are kidney failure, partial or complete loss of kidney function, and kidney stone disease. It is common for sufferers to experience no symptoms while losing kidney function and developing chronic kidney disease (CKD). Hypertension is the main symptom of CKD. Thus, the diagnosis and treatment of hypertension is a major concern for the prevention of CKD. The most common disorders of the urinary system are prostate enlargement and incontinence. An enlarged prostate in men causes various symptoms, such as frequent urination, nocturia, difficulty to empty the bladder. Urinary incontinence is the unintentional passing of urine. Early diagnosis and treatment of urinary symptoms are key in prevention of their progress.

Wednesday, June 20, 14:00-15:00

Meetings International - Nephrology Meeting 2018 Conference Session Speaker Bragner Bernard photo

Bragner Bernard

Nimes University Hospital, France

Title

Efficacy of taurolockTM in preventing primarybacterial peritonitis in patients undergoing peritoneal dialysis for renal insufficiency: A randomized, multicenter, double-blind study with placebo

Biography

Bernard R Branger has completed his MD at the age of 30 years from Montpellier -Nimes School of Medicine, University, Montpellier, France. He was chief of Nephrology department of Nimes University hospital and still president of AIDER regional association of dialysis. He has published more than 20 papers in reputed journals.

Abstract

Peritoneal dialysis is increasingly used in patients with chronic renal insufficiency, yet it is associated with the risk of peritonitis. In this parallel randomized controlled trial, a catheter locking solution (Taurolock™) was tested against a placebo in the reduction of peritonitis episodes and other secondary effects over two years. Patients from 11 French centers were randomized to Taurolock (n=75) or placebo (n=73). No significant difference was seen in the number of peritonitis events (24% IC95%= [15.2%-35.5%] Taurolock™ vs 27.4% IC95%= [17.9%-39.3%] placebo, p=0.78) or relapses (5.6% Taurolock™ vs 4.3% placebo, p=0.55). Similarly, death rate did not differ significantly between the groups (21.3% Taurolock™ vs 12.3% placebo, p=0.21) nor did the number of serious adverse events (58.7% Taurolock™ vs 63.0% placebo, p=0.71). However, pain upon injection was higher for patients in the Taurolock™ group at each visit (p<0.001). No difference was observed in bacterial analysis between groups: 31.4% of infections in the Taurolock™ group were Gram+, compared to 43.4% in the placebo group (p=0.34). Thus, administration of Taurolock™ every six months does not reduce the incidence of peritonitis or secondary events of peritoneal dialysis, but it does cause transient pain. The nature of the biofilm in peritonitis may have been misunderstood and further studies are required to better determine its role and how to reduce infections.

Wednesday, June 20, 15:00-15:30

Meetings International - Nephrology Meeting 2018 Conference Session Speaker Marie Claire Gubler photo

Marie Claire Gubler

Necker-Enfants Malades Hospital, France

Title

From autosomal recessive renal tubular dysgenesis to the renin-angiotensin system

Biography

Marie Claire Gubler Gribouval performed the genetic analysis of the RAS genes in the Laboratory of Hereditary Kidney Diseases (INSERM U 1163) headed by C Antignac. A Michaud performed the in vitro expression of the mutations in the laboratory headed by P Corvol. MC Gubler is the pathologist at the origin of the work.

Abstract

Renal tubular dysgenesis (RTD) is a severe disorder of renal development characterized by early onset foetal anuria leading to persistent oligohydramnios with the resulting sequence of malformations including lung hypoplasia. The usual issue is foetal or post-natal death due to hypotension, anuria and respiratory distress.Absence  of differentiated proximal tubules is the hallmark
of the disease. Familial cases, with an autosomal recessive inheritance, are frequent. Histological analysis of renal tissues directed us toward the renin-angiotensin system (RAS). Accordingly, genetic investigation confirmed that hereditary RDT was linked to mutations in the AGT, REN, ACE and AGTR1 genes. The absence of functional RAS leads to foetal and neonatal hypotension, renal hypoperfusion, and the development of anuria and tubular dysgenesis. Interestingly, DTR is also observed in foetuses exposed to RAS blockers, and
in various pathological conditions leading to chronic renal hypoperfusion such as severe cardiopathies, hepatic failure or in the donor foetus in the twin-to-twin transfusion syndrome. By expressing the mutations in cellular models, progresses in the knowledge of the structure-function relationship of the proteins have been obtained notably by showing that the defective misfolded proteins undergo either intracellular accumulation and retention or rapid degradation. These studies also confirmed that ACE has to be anchored in the
plasma membrane to be active. The identification of the disease on the basis of precise clinical and histological analyses and the characterization of the genetic defects allow genetic counseling and early prenatal diagnosis.

  • Nephrology | Clinical Nephrology | Pediatric Nephrology | Treatments in Nephrology
    Location: Rome
Speaker

Chair

John D. Sullivan

Boston University, USA

Speaker

Co-Chair

R. Michael Culpepper

University of South Alabama College of Medicine, USA

Thursday, June 21 , 10:00-10:35

Meetings International - Nephrology Meeting 2018 Conference Keynote Speaker Nikola M Pavlovic photo

Keynote Forum

Nikola M Pavlovic

University of Nis, Serbia

Title

Geographical distribution of urinary tract malignancies in Jablanica District – Southern Serbia –Possible link to renal diseases and Balkan endemic nephropathy

Biography

Nikola M. Pavlovic has graduated at the Medical Faculty, University Nis, Serbia in 1974, and become BMedSci 1979, Lecturer in Internal Medicine 1979, Specialist in Internal Medicine 1982, PhD of Medical Sciences 1986, and Associate Professor in Internal Medicine1988, British Council Scholar, Research Fellow, October 1982 – June 1984 at the Department of Renal and Nephrology Services, Royal Free Hospital, London, UK. As the Research Fellow, he was doing clinical and experimental work aimed at looking at the role of lipids in the initiation and the progression of renal diseases.

Abstract

Urinary tract cancers are common and comprise a wide range of lesions ranging in terms of size and malignancy from small benign tumors to aggressive neoplasms with high mortality. The predominant urinary tract malignancy is urinary bladder cancer. The exact etiopathogenetic mechanisms are not established yet, but there is most likely an interplay between environmental and genetic factors. Tobacco, obesity, occupational exposures ageing, and lifestyle factors remain the top contributing etiologic factors. In order get an insight into the type of cancer, incidence, gender ratio and geographical distribution we performed the descriptive epidemiology of several urinary tract cancers, utilizing incidence data from Pathology Unit Registry, General Hospital Leskovac, Jablanica county, Southern Serbia, 2007-2017. Over the period 2007-2017, there were 530 cases, 136 females and 394 males with the ratio 1:3. The overall incidences of all tumors increased in both sexes. There was a tendency for an exponential increase, but more so for males. (Fig.1). The urological cancers were recorded in 149 out of 193 settlements ranging from 1 to 174 cases. Remarkably, no cases were found in 44 settlements. We assume that differences in population-level exposure to environmental modifiable risk factors are a key driver of recorded cancer incidence. Several studies have demonstrated the carcinogenic potential of aristolochic acids (AAs) contained in Aristolochia plants. The AAs– derivative d-aristolactams are associated with a specific mutation in the p53 encountered in patients with Chinese herbs or Balkan endemic nephropathy (BEN) who present with UTUC. Although the incidence of BEN and UTUC has not been elucidated yet there is possible link between the two.

Thursday, June 21 ,

Meetings International - Nephrology Meeting 2018 Conference Keynote Speaker Simon Allen photo

Keynote Forum

Simon Allen

Fine Treatment, Uk

Title

Dr Allen’s device for kidney care as the first-line treatment for kidney stone disease

Biography

Simon Allen obtained a PhD in Medicine in 1978, Dr Simon Allen specialised in internal medicine. For years, he worked at and subsequently headed a hospital’s cardio-vascular department, and treated patients with various internal diseases, including renal diseases. He authored many scientific articles on metabolic disorders, including obesity, arthritis, renal, cardio-vascular and gastroenterological diseases. He lectured doctors pursuing higher medical qualifications. He then devoted two decades to pioneering medical research into various chronic internal diseases. He established Fine Treatment in Oxford, UK, authored The Origin of Diseases Theory, invented and patented therapeutic Dr Allen’s Devices as effective tools of Thermobalancing therapy.

Abstract

Kidney stone disease is a highly prevalent disease worldwide. Overall, the prevalence of kidney stones ranges from 1% to 13%, depending on race, gender and geographical location. Kidney stone disease affects men 3 times greater than women. However, studies of the past decade have showed an increase in the incidence of kidney stones around the world with a reduction in the gender gap. In the recent decade, Dr Allen’s Device for Kidney Care has been successfully used for the natural dissolution of kidney stones. Dr Allen’s Device that provides Thermobalancing therapy is a class 1 medical device, so it can be used by everyone at home. This is a safe therapeutic treatment of kidney stone disease, with absolutely no side effects and complications. Common standard treatments for kidney stone are: extracorporeal shock wave lithotripsy (ESWL) and percutaneous nephrolithotomy (PCNL). These methods were introduced in 1980s. The initially promising results of ESWL and PCNL are overshadowed by the widespread side effects and complications caused by these procedures. For instance, the long-term side effects after ESWL are hypertension, diabetes and chronic kidney disease (CKD), and after PCNL infection and residual stones. After both surgical methods of kidney stone removal, the additional treatments are needed. The results of over 10-year long clinical observations confirm that Thermobalancing therapy with Dr Allen’s Device is effective for patients with kidney stone disease. In addition, there is preliminary evidence that the therapy can improve kidney function in people with long-lasting kidney stone disease. Thermobalancing therapy gives an opportunity to treat kidney stone disease therapeutically – that will improve the quality of life of millions of men and women globally.

Thursday, June 21 , 11:25-12:00

Meetings International - Nephrology Meeting 2018 Conference Keynote Speaker Mabrouk Brahimi photo

Keynote Forum

Mabrouk Brahimi

Title

Feasibility of measuring the central pressure during dialysis with the Complior Analyzer

Biography

Mabrouk Brahimi has completed his PhD at the age of 25 years from RENE DESCARTES PARIS University and Postdoctoral Studies from School of Medicine. He is the Director of DIALYSE CENTER, a premier Bio-Soft service organization. He has published more than 25 papers in reputed journals and has been serving as an editorial board member of repute.

Abstract

Arterial stiffness and central pressure are independent predictor of mortality in renal patients1-4. Central systolic blood pressure (cSBP) could also be useful to monitor and possibly anticipate hypotension episodes during dialysis. However most cSBP devices are based on peripheral estimates which might be unreliable during the specific hemodynamic state of dialysis. Complior Analyse (Alam Medical, France) presents the advantage of measuring cSBP, hand-free, directly from the carotid artery with no mathematical estimation. Our study aims to document cSBP variability from Complior Analyse before and during dialysis. cSBP was measured in 19 stable patients (10M/9F, age:65±16yrs) with regular heart beats who underwent dialysis in Fresenius center, Montfermeil hospital, France (10 patients before dialysis, 13 patients 130±24min after the start of dialysis including 4 patients with data both before and during dialysis). Carotid waveforms were measured in triplicate within 5min and calibrated to mean (MAP) and diastolic pressures (DBP) obtained with a Philips SureSigns monitor on the fistula-free arm. Mean±SD values and coefficient of variation(CV) of repeated measurements are shown in the table below. Peripheral form factor (FF) was 37±13% (range 19-59) before dialysis and 39±21% (13-61) during dialysis while central FF was 45±7% (30-57) and 39±21% (21-46), respectively. Estimation of cSBP during dialysis was feasible with Complior Analyse. Its variability was similar to peripheral BP variability. The wide range of peripheral form factor values suggested that there is a need to improve peripheral BP estimation during dialysis.

  • Workshop
    Location: Rome

Thursday, June 21, 15:30-16:00

Meetings International - Nephrology Meeting 2018 Conference Session Speaker Goumri Nabila photo

Session Introduction

Goumri Nabila

Rodez Toulouse University, France

Title

Benefit of isonatric dialysis patients over 70 years

Biography

Goumri Nabila has completed the Nephrology Internal Residency at the age of 28years from Algiers Medecin, nephrologist in practice from Rodez Hospital Toulouse University and Nephrologist TOURS CHU (2016-2017), LOUIS PASTEUR Chartres ( 2017-2018).

Abstract

Intradialytic hypotension (IDH) is still a major medicalproblem  for hemodialysis patients over 70 years. isonatric dialysis has been an alternative able to reduce incidence of IDH and could help to improve hemodynamic stability in patients with cardiovascular comorbidities.
Method: 24 patients were included in prospective study ( jan - april 2016) , we evaluated the impact of isonatric HD on cardiovascular stability during 24 sessions compared to conventional HD 12 sessions.
Results: IDH 40,7% (Iso HD) VS 27,1% (conventional HD) P 0,005, the predialytic blood pressure pre HD PAS decrease from 12mmhg the differential between two groups P 0,014, the diastolic BP decrease from 3± 12 mmhg P=0,073), the dry weight did not vary significantly during the study 1.57±0,63
to 1.24±0,43, the number of intolerance symptoms was not significantly different except for vomiting 79/216 sessions (Iso HD) vs 134/432 (HD conventional) P 0,005, cramps 36/216 vs 24/432 sessions , nausea 67/216 vs 117/432, how we can see isonatric dialysis has an implication for hemodialysis tolerance also with patients over 70 years so it can be an option to management intradialytic hypotension we should think to revisiting prescription of Na dialysate.

Thursday, June 21,

Punit Gupta

Pt. J.N.M. Medical College, India

Title

Co-relation of lipid profile with proteinuria in sickle cell nephropathy patients for local area of India

Biography

Punit Gupta is MBBS, MD (Medicine), DM (Nephrology) and PhD. He is the Honorary Nephrologists to the Governor of Chhattisgarh State since 2009. He is Chairman and Members of many important academic and management committees of various Government Medical Institutions in the country and the Pt. Deen Dayal Upadhyay Health Sciences University, Raipur. He has guided over 100 Postgraduate &amp; Technologist student for their thesis &amp; Project in Nephrology &amp; Research and also severed as an examiner for the university examinations. A man of researches and publication, he has presented more than 160 research papers and abstracts on kidney diseases in tribal populations at renowned national and international conferences. He has developed and economic, efficient and effective walkie talkie system for consultation and directions to the hospital staff and doctors. He has been awarded Dr. B. C. Roy National Award for his research to give aid or assistance to research project for the year 2016.

Abstract

Materials & Methods: Total75 patients were admitted. All patients were subjected to routine blood investigations, blood glucose, urine analysis, routine biochemical investigations, sickling, lipid profile, ECG, Serum Protein, X Ray chest, USG(KUB), serum calcium, potassium, chloride, sodium,phosphorus,albumin,globulin, bilirubin triglyceride,HDL,LDL,VLDL,SGOT,SGPT, Hb Electrophoresis, Serum Thyroid levels.
Result:
• Mean age of the patients was 26.8 ± 11.6 years.
• Males were 29.41% & Females were 70.59%, Ratio being M: F:: 1:2.75.
• In patients of Sickle cell nephropathy, 41.4% patients had deranged lipid profile.
• In Sickle cell trait,27.2 % had deranged lipid profile.
• Among Sickle cell disease, all the patients had deranged lipid profile.
• Derangement in individual lipids are as follows:-
1) Hypercholesterolemia(≥ 200 mg/dl) - 7.31 %,
2) TG(≥160 mg/dl) - 7.31%,
3) LDL (˃130 mg/dl ) – 2.4%
4) HDL(≤40 mg/dl) - 58.5% .
Proteinuria in patients of Sickle cell nephropathy:
<1 gm/d = 21.9% had deranged lipid profile.
>1 gm/d = 34.1 % patients had deranged lipid profile.
Conclusion:
1) Lipid derangement is almost seen in all the patients of Sickle cell Nephropathy.
2) Hypercholesterolemia & Hypertriglyceridemia is common in males then in female.
3) Low levels of HDL was common in females as compare to male.
4) Deranged lipid profile was more common in proteinuria more than 1gm/dl

Thursday, June 21,

Meetings International - Nephrology Meeting 2018 Conference Session Speaker M Ciocchini photo

M Ciocchini

University of Buenos Aires, Argentina

Title

MGRS: One of the nephrological challenges of the 21st century

Biography

Mariana Ciocchini is MD by the National University of La Plata and Nephrologist by the University of Buenos Aires. Her research is focused on monoclonal gammopathy of renal significance and she has published papers about this subject in a reputed journal. She is a member of the Glomerulopathy Council, ANBA, Argentinian Society of Nephrology being one of the co-authors of the book “Glomerular diseases” recently published by this group.

Abstract

Monoclonal gammopathy of renal significance (MGRS) is a recently described hemato-nephrological metaentity whose pathogenesis depends on monoclonal
immunoglobulins (Ig) or humoral factors secreted by small B-cell clones affecting any nephronal area with a broad spectrum of histopathological patterns and even the presence of, at least, two different kinds of MGRS in the same patient. The importance of MGRS is based on its association with an increased morbidity and mortality, included its recurrence in post-renal transplant period and even as “de novo” presentation; and its improvement after performing the cell-B clone treatment. The relevance of renal biopsy in nephrological practice depends on its reliability to achieve a precise MGRS diagnosis which may be the only indication for hematological treatment. Kidney injury mediated by monoclonal Ig is mainly the result of its deposit in renal tissue, as is the case of light chain deposition disease. Monoclonal Ig can also have auto-antibody activity which is responsible for a cluster of disorders related to the dysregulation of the alternative pathway of complement, for example, C3 glomerulopathy with a big impact in the difficult treatment of its. The third pathophysiological mechanism depends on humoral factors like in POEMS syndrome’s nephropathy. Taking into account only one type of paraproteinemia, the monoclonal gammopathy of undetermined significance, MGRS’s prevalence is being estimated around 0.32 and 0.57 % depending on the population age. MGRS as a meta-entity is changing nephrological paradigms related to diagnosis, treatment and prognosis, and this is a fascinating challenge which a multidisciplinary approach.

  • Special Session
    Location: Rome
  • Nephrology Nursing | Diabetes and Hypertension | Renal Dialysis and Care | Renal Surgery
    Location: Rome
Speaker

Chair

Ghodrat A.Siami

Vanderbilt School of Medicine, USA

Speaker

Co-Chair

Joelle Nortier

Free University of Brussels, Belgium

  • Special Session
    Location: Rome

Friday, June 22,

Meetings International - Nephrology Meeting 2018 Conference Session Speaker Nikolai Bazaev photo

Session Introduction

Nikolai Bazaev

Moscow State Medical University, Russia

Title

Applicability of electrolysis for artificial blood purification

Biography

Nikolai Bazaev has completed his PhD at the age of 27 years from National Research University MIET, Russia. He is the chief executive for wearable artificial kidney and artificial pancreas projects. He has published more than 30 papers in peer-reviewed journals.

Abstract

Hemodialysis and peritoneal dialysis are the two main methods of renal replacement therapy. Several teams around the world are developing and testing a prototype of wearable artificial kidney (WAK), the central component of which is the dialysis regeneration unit (DRU). Its task is to restore the initial physical and chemical state of the dialysate solution. The main markers of the therapy effectiveness are the concentrations of creatinine, uric acid and urea. The first two substances are easily removed with activated carbon, but for urea elimination, it is necessary to use special methods: enzymatic or electrochemical. The enzymatic method uses urease, which catalyzes the hydrolysis of urea to carbon dioxide and ammonia, which are subsequently adsorbed by activated carbon. The disadvantage of this method is the complexity of manufacturing and storing urease. In the electrochemical method, electrolysis of waste dialysate is used in an electrochemical cell. The key complexity of this method is the selection of a method for the long-term and controlled removal of urea from spent dialysate. Urea can be electrochemically oxidized in a neutral medium using catalysts made of platinum group metals such as Ru-TiO2, Ti-Pt, Ti-(Pt-Ir), or from carbon materials such as coal, carbon foam, graphite, etc. In this work, electrodes made of various materials are studied to evaluate the applicability of their use as part of an electrochemical regenerator in WAK. Among the materials studied were platinum deposited on titanium by electrodeposition and by the blasting; rhodium, deposited on titanium by electrodeposition; ruthenium deposited on titanium by electrodeposition method, as well as electrodes from foamed coal; silicon-carbon films deposited on titanium substrates by vacuum spraying, doped with molybdenum; silicon-diamond films deposited on titanium substrates; platinum, sputtered on titanium substrates.

  • Kidney Cancer | Kidney Transplantation | Renal Nutrition & Metabolism
Speaker

Chair

Nikolai Bazaev

Moscow State Medical University, Russia

Speaker

Co-Chair

M Ciocchini

University of Buenos Aires, Argentina